Shaanxi BLOOM Tech Co., Ltd. is one of the most experienced manufacturers and suppliers of injection aviptadil in China. Welcome to wholesale bulk high quality injection aviptadil for sale here from our factory. Good service and reasonable price are available.
As a type of synthetic peptide with special physiological activity, injection aviptadil exhibits unique and significant efficacy in regulating the pulmonary vascular system. Its core target is precisely focused on the diastolic regulation of pulmonary blood vessels, distinguishing it from the generalized action characteristics of conventional vasoactive substances.
This substance, with its highly specific targeting properties, can accurately identify and act on specific structures of pulmonary blood vessels, avoiding non-specific activation of blood vessels in other parts of the body, thereby achieving physiological reduction of pulmonary arterial pressure and comprehensive optimization of pulmonary blood circulation pathways.
Our Product Forms
Aviptadil COA
 |
||
| Certificate of Analysis | ||
| Compound name | Aviptadil | |
| Grade | Pharmaceutical grade | |
| CAS No. | 40077-57-4 | |
| Quantity | 36g | |
| Packaging standard | PE bag+Al foil bag | |
| Manufacturer | Shaanxi BLOOM TECH Co., Ltd | |
| Lot No. | 202501090066 | |
| MFG | Jan 9th 2025 | |
| EXP | Jan 8th 2028 | |
| Structure |
|
|
| Item | Enterprise standard | Analysis result |
| Appearance | White or almost white powder | Conformed |
| Water content | ≤5.0% | 0.54% |
| Loss on drying | ≤1.0% | 0.42% |
| Heavy Metals | Pb≤0.5ppm | N.D. |
| As≤0.5ppm | N.D. | |
| Hg≤0.5ppm | N.D. | |
| Cd≤0.5ppm | N.D. | |
| Purity (HPLC) | ≥99.0% | 99.98% |
| Single impurity | <0.8% | 0.52% |
| Total microbial count | ≤750cfu/g | 95 |
| E. Coli | ≤2MPN/g | N.D. |
| Salmonella | N.D. | N.D. |
| Ethanol (by GC) | ≤5000ppm | 500ppm |
| Storage | Store in a sealed, dark, and dry place below -20°C | |
|
|
||
|
|
||
| Chemical Formula | C147H238N44O42S |
| Exact Mass | 3323.76 |
| Molecular Weight | 3325.85 |
| m/z | 3324.76 (100.0%), 3323.76 (62.9%), 3325.76 (52.1%), 3326.77 (41.3%), 3325.76 (26.9%), 3325.76 (15.1%), 3324.75 (9.5%), 3327.77 (9.4%), 3326.76 (8.6%), 3326.76 (7.9%), 3327.77 (6.7%), 3325.76 (5.4%), 3327.76 (5.4%), 3326.76 (4.7%), 3326.76 (4.5%), 3327.77 (4.5%), 3328.77 (3.6%), 3328.77 (3.1%), 3325.75 (2.8%), 3325.77 (2.7%), 3327.76 (2.4%), 3327.77 (2.3%), 3326.77 (2.2%), 3328.77 (1.9%), 3324.76 (1.7%), 3325.76 (1.6%), 3328.76 (1.5%), 3328.77 (1.5%), 3327.76 (1.3%), 3327.76 (1.3%), 3327.76 (1.2%), 3328.77 (1.1%), 3326.75 (1.1%), 3325.76 (1.1%), 3324.76 (1.0%) |
| Elemental Analysis | C, 53.09; H, 7.21; N, 18.53; O, 20.20; S, 0.96 |
Compared to other similar vasodilators, this has a more targeted mode of action, and its multidimensional regulatory efficacy is not only reflected in the intensity and duration of vasodilation, but also in its synergistic regulation of the pulmonary vascular microenvironment. This unique advantage of action makes it an important regulator of pulmonary vascular physiology and pathology, and its specific mechanism of action and multidimensional efficacy deserve further exploration and interpretation.
As a key hub for gas exchange and blood circulation in the body, the vascular homeostasis of the lungs directly determines the normal operation of pulmonary physiological functions. It provides important support for improving the efficiency of lung gas exchange, timely elimination of metabolic waste, and nutrient supply to lung tissues through precise regulation of pulmonary vasodilation, effectively maintaining the dynamic homeostasis of lung related physiological functions.
Targeted characteristics of pulmonary vasodilation
The vasodilation effect of injection aviptadil on pulmonary blood vessels is not a generalized effect, but exhibits a high degree of targeted selectivity, which enables it to precisely target the pulmonary vascular system and minimize non-specific effects on blood vessels in other parts of the body. Specifically, its targeting is mainly reflected in three aspects:
One is the specificity of the site of action. Compared to various blood vessels in the systemic circulation, this substance has a more significant effect on various levels of blood vessels in the lungs, especially on key blood vessel segments involved in lung gas exchange such as pulmonary arterioles and pulmonary capillaries. It has strong targeted relaxation and can quickly relax vascular wall tension.
The second is the specificity of receptor binding. It forms targeted binding with specific receptors on the pulmonary vascular wall, triggering receptor-mediated signaling pathways, thereby inhibiting the contractile activity of vascular smooth muscle and promoting moderate dilation of the vascular lumen. This binding mode can effectively avoid cross reactivity with other vascular receptors and improve the accuracy of the action.
The third is the hierarchical nature of the scope of action. It can exert a relaxing effect on blood vessels of different levels in the lungs, from mild relaxation of pulmonary arteries to significant relaxation of pulmonary arterioles, and then to moderate dilation of pulmonary capillaries, forming a multi-level and all-round pattern of pulmonary vascular relaxation, laying the foundation for subsequent improvement of pulmonary circulation.
The above information is sourced from:
Nazzareno Galie. Effects Of Inhaled Aviptadil (Vasoactive Intestinal Peptide) In Patients With Pulmonary Arterial Hypertension (PAH). American Journal of Respiratory and Critical Care Medicine, 2010, 181: A2516
The relief pathway of pulmonary arterial hypertension
Abnormal increase in pulmonary arterial pressure is the core cause of pulmonary blood circulation disorders, and injection aviptadil can effectively alleviate this pathological state through multi-path synergistic effects, achieving physiological regulation of pulmonary arterial pressure.
01.Core pressure regulation mechanism.
This substance relaxes the pulmonary blood vessels, enlarges the inner diameter of the blood vessel lumen, reduces the resistance load when blood flows through the pulmonary blood vessels, and thus breaks the pathological cycle of "vascular stenosis pressure increase blood flow stagnation", promoting the gradual decrease of pulmonary artery pressure to the normal range;
02.Optimization of pulmonary circulation resistance.
Excessive contraction of pulmonary vascular smooth muscle is a key factor leading to increased pulmonary circulation resistance. Injection aviptadil can inhibit abnormal contraction of smooth muscle cells, reduce vascular wall tension, improve endothelial permeability, reduce the potential risk of intravascular thrombosis, further reduce peripheral resistance of pulmonary circulation, and provide auxiliary support for pressure regulation;
03.Synergistic regulation of vascular endothelial factors.
It can regulate the secretion of factors in pulmonary vascular endothelial cells, promote the release of vasodilator factors, inhibit the generation of vasoconstrictor factors, and further enhance the vasodilation effect of pulmonary blood vessels through this factor balance regulation, achieving synergistic relief of pulmonary arterial hypertension and avoiding damage to lung tissue caused by pressure fluctuations.
The above information is sourced from:
Fahad I. Al-Saikhan, Mohamed A. Abd-Elaziz, Ramadan Al-Shdeifat, et al. Preparation and Evaluation of Aviptadil Acetate Loaded PLGA Microparticles: A Preliminary Study to Treat Pulmonary Hypertension. Latin American Journal of Pharmacy, 2022
Jian Hu, et al. Novel Targets of Drug Treatment for Pulmonary Hypertension. Am J Cardiovasc Drugs, 2023
Multidimensional efficacy of improving pulmonary circulation
The vasodilation effect of Aviptadil in the lungs will ultimately achieve comprehensive optimization of pulmonary circulation through multidimensional pathways, ensuring the normal operation of pulmonary physiological functions.
Firstly, precise regulation of blood flow velocity ensures smooth blood circulation in the lungs and adequate blood supply to lung tissues by optimizing the flow rate of blood through the lungs after vasodilation. This not only avoids slow and stagnant blood flow caused by vascular stenosis, but also prevents the impact of excessive flow velocity on the blood vessel wall.
Secondly, optimization of alveolar blood perfusion. As the core site of lung gas exchange, the amount of blood perfusion in alveoli directly affects the efficiency of gas exchange. This substance dilates pulmonary capillaries, increases blood perfusion around alveoli, enhances the efficiency of oxygen and carbon dioxide exchange between alveoli and blood, improves lung oxygenation function, and promotes the elimination of metabolic waste in the lungs, maintaining physiological homeostasis in the lungs.
Finally, the coordinated balance of pulmonary circulation and the relaxation of pulmonary blood vessels can indirectly regulate the pressure balance between the systemic and pulmonary circulation, reduce complications such as systemic congestion caused by pulmonary arterial hypertension, ensure the coordinated operation of systemic blood circulation, and provide guarantees for the overall physiological functions of the body.
The above information is sourced from:
Pulido T, Adzerikho I, Channick RN, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med, 2013, 369(9): 809-818
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, et al. Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. Am J Respir Crit Care Med, 2020, 201(6): 707-717
References
Keijzers GB. Aviptadil (Sena Tek). Current Opinion in Investigational Drugs, 2001, 2(4): 545-549
Galiè N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation, 2009, 119(22): 2894-2903
Galiè N, Barberà JA, Frost AE, et al. Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension. N Engl J Med, 2015, 373(9): 834-844
Huang X, Balasubramanian A, Moutchia J, et al. Ambient Air Pollution Exposure and Mortality in the Pulmonary Hypertension Association Registry. Ann Am Thorac Soc, 2025, 22(9): 1351-
FAQ
- What is aviptadil used to treat?
Aviptadil, a synthetic form of VIP, also named as RLF-100, is at present under phase II/III clinical trials. This drug has been designated as an orphan drug by FDA and has been used in past to treat respiratory airway diseases, such as asthma, chronic obstructive pulmonary disease (COPD), ARDS, and sarcoidosis.
- Is aviptadil an antiviral?
Preliminary results of the COVID-AIV trial, which has been recruiting patients with COVID-19 and respiratory failure, indicate a promising antiviral effect of the intravenous administration of aviptadil.
- How long does it take for aviptadil to work?
On day 28, the improvement in the radiological findings of the aviptadil group was statistically significant compared to the placebo group. This highlights the importance of inhaled aviptadil.
Hot Tags: injection aviptadil, suppliers, manufacturers, factory, wholesale, buy, price, bulk, for sale